Quercetin Effects on Cell Cycle Arrest and Apoptosis and Doxorubicin Activity in T47D Cancer Stem Cells.
Apoptosis
Breast Cancer cells
Cancer stem cells
Drug resistance
Quercetin
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
received:
12
06
2022
entrez:
29
12
2022
pubmed:
30
12
2022
medline:
3
1
2023
Statut:
epublish
Résumé
Targeting breast cancer stem cells with the CD44+/CD24- phenotype is critical for complete eradication of cancer cells due to its Self-renewal, differentiation, and therapeutic resistance ability. Quercetin is a popular flavonoid with lower adverse effects and has anti-tumor properties. Therefore, we assessed the anticancer activity of Quercetin and Doxorubicin alone and in combination in the T47D cells of human breast cancer and their isolated Cancer stem cells (CSCs). The human breast cancer cell line T47D was used for this experiment. T47D CSCs were isolated by magnetic bead sorting using the MACS system. The anticancer activity of Quercetin and Doxorubicin alone and in combination were evaluated using MTT cytotoxicity assay and cell cycle distribution and apoptosis induction by flow cytometry analysis. We have shown that almost 1% of T47D cell populations are made up of CD44+/CD24- cells, which considered as cancer stem cells. Quercetin and Doxorubicin alone or in combination inhibited cell proliferation and induced apoptosis in breast cancer T47D cells and in lower extent in CD44+/CD24- cells. Quercetin significantly strengthened Doxorubicin's cytotoxicity and apoptosis induction in both cell populations. Quercetin and Doxorubicin and their combination induced G2/M arrest in the T47D cells and to a lesser extent in isolated CSCs. A value of p < 0.05 was considered as indicating a statistically significant difference. These outcomes suggested that CSCs are a minor population of cancer cells, which play a significant role in drug resistance by being quiescent, slow cycling and resistance to apoptosis. Furthermore, our data showed that adding Quercetin to Doxorubicin is an effective approach for the treatment of both CSCs and bulk tumor cells.
Sections du résumé
BACKGROUNDS
BACKGROUND
Targeting breast cancer stem cells with the CD44+/CD24- phenotype is critical for complete eradication of cancer cells due to its Self-renewal, differentiation, and therapeutic resistance ability. Quercetin is a popular flavonoid with lower adverse effects and has anti-tumor properties. Therefore, we assessed the anticancer activity of Quercetin and Doxorubicin alone and in combination in the T47D cells of human breast cancer and their isolated Cancer stem cells (CSCs).
MATERIALS AND METHODS
METHODS
The human breast cancer cell line T47D was used for this experiment. T47D CSCs were isolated by magnetic bead sorting using the MACS system. The anticancer activity of Quercetin and Doxorubicin alone and in combination were evaluated using MTT cytotoxicity assay and cell cycle distribution and apoptosis induction by flow cytometry analysis.
RESULTS
RESULTS
We have shown that almost 1% of T47D cell populations are made up of CD44+/CD24- cells, which considered as cancer stem cells. Quercetin and Doxorubicin alone or in combination inhibited cell proliferation and induced apoptosis in breast cancer T47D cells and in lower extent in CD44+/CD24- cells. Quercetin significantly strengthened Doxorubicin's cytotoxicity and apoptosis induction in both cell populations. Quercetin and Doxorubicin and their combination induced G2/M arrest in the T47D cells and to a lesser extent in isolated CSCs. A value of p < 0.05 was considered as indicating a statistically significant difference.
CONCLUSION
CONCLUSIONS
These outcomes suggested that CSCs are a minor population of cancer cells, which play a significant role in drug resistance by being quiescent, slow cycling and resistance to apoptosis. Furthermore, our data showed that adding Quercetin to Doxorubicin is an effective approach for the treatment of both CSCs and bulk tumor cells.
Identifiants
pubmed: 36579996
doi: 10.31557/APJCP.2022.23.12.4145
pmc: PMC9971456
pii:
doi:
Substances chimiques
Quercetin
9IKM0I5T1E
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4145-4154Références
Biomed Pharmacother. 2018 Nov;107:793-805
pubmed: 30142541
Biochem Pharmacol. 2010 Aug 15;80(4):423-30
pubmed: 20394737
Cancer Lett. 2008 Oct 8;269(2):315-25
pubmed: 18467024
Bioorg Chem. 2020 Jan;94:103426
pubmed: 31784064
Life Sci. 2020 May 1;248:117463
pubmed: 32097663
Neoplasia. 2020 Dec;22(12):663-678
pubmed: 33142233
J Gastrointest Cancer. 2017 Dec;48(4):314-320
pubmed: 28828709
Breast Cancer Res Treat. 2016 Oct;159(3):395-406
pubmed: 27562585
Stem Cells Transl Med. 2017 Dec;6(12):2115-2125
pubmed: 29072369
Mol Med Rep. 2019 Mar;19(3):2097-2106
pubmed: 30664221
Eur J Pharmacol. 2019 Mar 15;847:11-18
pubmed: 30639311
Curr Med Chem. 2009;16(25):3267-85
pubmed: 19548866
Carcinogenesis. 2021 Jul 16;42(7):905-912
pubmed: 34014276
PLoS One. 2011;6(11):e27719
pubmed: 22140461
Oncol Rep. 2017 Aug;38(2):819-828
pubmed: 28677813
Biomolecules. 2019 May 06;9(5):
pubmed: 31064104
Cancer Immun. 2009 Apr 23;9:4
pubmed: 19385591
Front Oncol. 2020 Jun 02;10:764
pubmed: 32582535
Oncol Rep. 2004 Mar;11(3):727-33
pubmed: 14767529
Molecules. 2021 Sep 24;26(19):
pubmed: 34641325
Neoplasma. 2005;52(6):489-93
pubmed: 16284694
Arch Toxicol. 2015 Jul;89(7):1103-17
pubmed: 25138434
Biomed Pharmacother. 2019 Jun;114:108800
pubmed: 30921705
Int Immunopharmacol. 2010 Jul;10(7):819-26
pubmed: 20447470
Cancer Lett. 2006 Aug 28;240(2):234-42
pubmed: 16274926
Trends Mol Med. 2008 Oct;14(10):450-60
pubmed: 18775674
J Cell Biochem. 2022 Feb;123(2):259-274
pubmed: 34636440
EMBO Mol Med. 2020 Sep 7;12(9):e11908
pubmed: 32667137
Iran J Basic Med Sci. 2015 Jul;18(7):635-43
pubmed: 26351552
Exp Cell Res. 2006 Nov 15;312(19):3701-10
pubmed: 17046749
Cell Biol Toxicol. 2008 Apr;24(2):165-74
pubmed: 17805981
Oncol Lett. 2013 Mar;5(3):787-792
pubmed: 23426586
Biomed Pharmacother. 2020 Jan;121:109604
pubmed: 31733570
Curr Med Chem. 2010;17(9):812-25
pubmed: 20156174
Asian Pac J Cancer Prev. 2020 Jul 01;21(7):1867-1875
pubmed: 32711409
Cancer Biol Ther. 2014 Aug;15(8):1000-12
pubmed: 24801380
Ann Oncol. 2020 Mar;31(3):387-394
pubmed: 32067680
Mediterr J Hematol Infect Dis. 2021 Jul 01;13(1):e2021049
pubmed: 34276918
Int J Biochem Cell Biol. 2019 Feb;107:38-52
pubmed: 30529656
Life Sci. 2010 Sep 11;87(11-12):333-8
pubmed: 20637779
Nutrients. 2020 Mar 13;12(3):
pubmed: 32183060
Food Chem. 2012 Apr 15;131(4):1453-1459
pubmed: 22140296